Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation
The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.
